The immune system plays a crucial role in detecting and destroying cancer. But tumor cells grow fast and often avoid immune detection. CAR-T cell therapy helps the immune system by engineering a patient’s own T cells to find and kill cancer cells.
CAR stands for chimeric antigen receptor. It combines a tumor-targeting antibody with T-cell activation signals. The result: a highly potent T cell that can find and destroy tumor cells with precision.
BioNTech, a global leader in immunotherapy, has advanced this approach by developing a CAR-T therapy that targets a molecule called Claudin-6. This molecule is not found in healthy tissues but appears on many solid tumors, such as ovarian, lung, testicular, and endometrial cancer. This makes Claudin-6 an ideal target for safe and effective treatment.
Here’s how the therapy works: once Claudin-6 is confirmed in the tumor, T cells are collected from the patient. These cells are then modified at BioNTech’s GMP facility to express the Claudin-6 CAR. After expansion, the modified CAR-T cells are infused back into the patient to locate and destroy cancer cells.
This new Claudin-6 CAR-T therapy represents a major step toward treating solid tumors, offering hope for patients with cancers that are hard to treat.
Learn more at www.biontech.com
